Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

Autor: Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Division of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA., Ahn KW; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA., Kaur M; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA., Lekakis L; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Iqbal M; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS, USA., Hill B; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Hossain NM; Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Riedell P; Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA., Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Division of Hematology and Medical Oncology, University of Washington, Seattle, WA, USA., Grover N; Lineberger Comprehensive Cancer Center, Department of Medicine, Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Frigault M; Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA, USA., Brammer J; Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Merryman R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lazaryan A; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Ram R; Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Hertzberg M; Prince of Wales Hospital, Sydney, NSW, Australia., Savani B; Long Term Transplant Clinic, Vanderbilt University Medical Center, Nashville, TN, USA., Awan F; Division of Hematology and Oncology, UT Southwestern, Dallas, TX, USA., Khimani F; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Ahmed S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kenkre VP; Division of Hematology, Oncology, Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI, USA., Ulrickson M; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Shah N; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Kharfan-Dabaja MA; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA., Herrera A; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA., Sauter C; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Hamadani M; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA. mhamadani@mcw.edu.; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. mhamadani@mcw.edu.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Jul 08; Vol. 14 (1), pp. 108. Date of Electronic Publication: 2024 Jul 08.

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.

Autor: Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Diefenbach CS; Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA., Asch A; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Kumar A; University of Arizona, Tucson, Arizona, USA., Tsai ML; Swedish Cancer Institute, Seattle, Washington, USA., Jandl TA; Stony Brook University Hospital, Stony Brook, New York, USA., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA., Kenkre VP; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA., Awan F; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Novotny W; BeiGene, LTD, Cambridge, Massachusetts, USA., Huang J; BeiGene, LTD, Cambridge, Massachusetts, USA., Miao L; MEI Pharma, Inc., San Diego, California, USA., Rajagopalan P; PR Consulting, Mountain Lakes, New Jersey, USA., Ghalie RG; MEI Pharma, Inc., San Diego, California, USA., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1762-1770. Date of Electronic Publication: 2024 Mar 19.

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma.

Autor: Liu Y; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Kimpara S; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Hoang NM; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Daenthanasanmak A; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Li Y; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Lu L; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Ngo VN; Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA., Bates PD; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI., Song L; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI., Gao X; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Bebel S; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Chen M; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Chen R; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Zhang X; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Selberg PE; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Kenkre VP; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Waldmann TA; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Capitini CM; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI., Rui L; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.

Publikováno v: Blood [Blood] 2023 Nov 30; Vol. 142 (22), pp. 1879-1894.

Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.

Autor: Desai SH; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA., Spinner MA; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., David K; Department of Hematology and Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Goyal G; O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA., Kahl B; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Dorritie K; Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Azzi J; Division of Hematology and Medical Oncology, Icahn School of Medicine Mount Sinai, New York, New York, USA., Kenkre VP; Department of Hematology, University of Wisconsin, Madison, Wisconsin, USA., Arai S; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Chang C; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Fusco B; Department of Hematology and Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Sumransub N; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Hatic H; O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA., Saba R; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Ibrahim U; Division of Hematology and Medical Oncology, Icahn School of Medicine Mount Sinai, New York, New York, USA., Harris EI; Department of Hematology, University of Wisconsin, Madison, Wisconsin, USA., Shah H; Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Murphy J; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA., Ansell S; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Jagadish D; Cleveland Clinic Foundation, Cleveland, Ohio, USA., Orellana-Noia V; Division of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Diefenbach C; Perlmutter Cancer Center, NYU Grossman Medical School, New York, New York, USA., Iyenger S; Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Rappazzo KC; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA., Mishra R; Cleveland Clinic Foundation, Cleveland, Ohio, USA., Choi Y; Perlmutter Cancer Center, NYU Grossman Medical School, New York, New York, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Advani RH; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Micallef IN; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2023 Mar; Vol. 98 (3), pp. 464-471. Date of Electronic Publication: 2023 Jan 11.

Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

Autor: Epperla N; Division of Hematology, The Ohio State University, Columbus, OH., Zhao Q; Division of Hematology, The Ohio State University, Columbus, OH., Chowdhury SM; Division of Hematology, The Ohio State University, Columbus, OH., Shea L; Division of Hematology, Washington University, St. Louis, MO., Moyo TK; Levine Cancer Center, Atrium Health, Charlotte, NC., Reddy N; Vanderbilt University Medical Center, Nashville, TN., Sheets J; Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC., Weiner DM; Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Geethakumari PR; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Kandarpa M; Division of Hematology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Bruno XJ; Division of Hematology and Oncology, University of Vermont, Burlington, VT., Thomas C; Division of Hematology, Thomas Jefferson University, Philadelphia, PA., Churnetski MC; Winship Cancer Institute, Emory University Medical Center, Atlanta, GA., Hsu A; Division of Hematology, Brown University, Providence, RI., Zurbriggen L; Division of Hematology, University of Wisconsin, Madison, WI., Tan XC; Cancer Institute of New Jersey, New Brunswick, NJ., Lindsey K; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC., Maakaron J; Division of Hematology, University of Minnesota, Minneapolis, MN., Caimi PF; University Hospitals Seidman Cancer Center, Cleveland, OH., Torka P; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY., Bello C; Division of Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Ayyappan S; Division of Hematology and Oncology, University of Iowa, Iowa City, IA., Oh TS; Division of Hematology, Northwestern University, Chicago, IL., Karmali R; Division of Hematology, Northwestern University, Chicago, IL., Kim SH; Division of Hematology and Oncology, Rush University, Chicago, IL., Kress A; Division of Hematology, Yale University, New Haven, CT., Kothari S; Division of Hematology, Yale University, New Haven, CT., Sawalha Y; Division of Hematology, The Ohio State University, Columbus, OH., Christian B; Division of Hematology, The Ohio State University, Columbus, OH., David KA; Cancer Institute of New Jersey, New Brunswick, NJ., Greenwell IB; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC., Janakiram M; Division of Hematology, University of Minnesota, Minneapolis, MN., Kenkre VP; Division of Hematology, University of Wisconsin, Madison, WI., Olszewski AJ; Division of Hematology, Brown University, Providence, RI., Cohen JB; Winship Cancer Institute, Emory University Medical Center, Atlanta, GA., Palmisiano N; Division of Hematology, Thomas Jefferson University, Philadelphia, PA., Umyarova E; Division of Hematology and Oncology, University of Vermont, Burlington, VT., Wilcox RA; Division of Hematology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Alderuccio JP; Division of Hematology, University of Miami, Miami, FL., Barta SK; Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Grover NS; Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC., Ghosh N; Levine Cancer Center, Atrium Health, Charlotte, NC., Bartlett NL; Division of Hematology, Washington University, St. Louis, MO., Herrera AF; Division of Hematology, City of Hope, Duarte, CA., Shouse G; Division of Hematology, City of Hope, Duarte, CA.

Publikováno v: Blood advances [Blood Adv] 2023 Jan 10; Vol. 7 (1), pp. 88-91.